The Massachusetts Group Insurance Commission (GIC) has voted to end coverage of GLP-1 drugs for weight loss, a decision driven by increasing costs that officials say are straining the state budget. The move joins commercial insurers such as Blue Cross of Massachusetts, Point32Health, and Health New England in cutting the benefit. Approximately 22,000 GIC members currently use GLP1 medications for weightloss, costing the state about $46 million. Critics warned that the move could exacerbate health disparities and potentially increase costs later if members with chronic conditions worsen. The decision is part of a strategy to give insurers more influence over drugmakers.